Demographics | |
 Age*, sex*, ethnicities | |
 BMI*, smoking history* | |
Clinical features | |
 Family history of first-degree relatives | |
 Length of time since first onset until the trial commencement, length of time since first onset until first treatment* | |
 Disease activity: • Number of tender joints*, number of swelling joints*, self-report level of pain based on visual analogue scale (VAS)* • Disease Activity Score (continuous)*, disease activity level (categorical)* | |
 Joint involvement: • Large joint involvement: knee, hip joints, etc. • Uncommon joint involvement | |
 Nonspecific systemic symptoms: fever, fatigue, etc. | |
 Comorbidities*: osteoporosis, osteoarthritis, etc. | |
 Functional/global quality of life (QoL) conditions at baseline* | |
 Prior treatment history: failure times, failed drug types, etc. | |
 Cointerventions decided before randomization: • Steroids, nonsteroidal anti-inflammatory drug (NSAIDs) | |
Biochemical features | |
 Serum inflammatory factors*: • Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP); others such as TNF, IL-6, etc. | |
 Serum antibodies*: • Rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA) spectrum | |
Radiographic features | |
 Joint fusion (already deformed), bone erosion*, synovitis*, early bone inflammation | |
 Radiographic scores* | |
Genetics# | |
 HLA (human leukocyte antigen) types and SNPs (single nucleotide polymorphisms) if they are tested. |